A SUMMIT trial analysis showed how tirzepatide improves cardiovascular and kidney health in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).
Tirzepatide is demonstrating new promise for patients with obesity-related heart failure with preserved ejection fraction (HFpEF).1
Presented at the American Heart Association (AHA) Scientific Sessions 2024, a secondary analysis of the SUMMIT trial shed light on the drug’s ability to address key underlying mechanisms of obesity-related HFpEF, including circulatory volume overload, systemic inflammation, and end-organ damage. These findings expand on overall SUMMIT trial results showing that tirzepatide reduced the combined risk of cardiovascular death or worsening HF by 38%, as well as improving health status and exercise capacity.2 This analysis offers new insights into how the long-acting glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist achieves these benefits and improves outcomes.1
Over half of patients with HF have a preserved ejection fraction, and nearly two-thirds of those patients have obesity. The SUMMIT trial included 731 patients with obesity-related HFpEF, with a median body mass index of 38 kg/m² and high rates of comorbidities such as hypertension, chronic kidney disease (CKD), and coronary artery disease. The SUMMIT trial was funded by Eli Lilly and Company, the supplier of tirzepatide under brand names Mounjaro and Zepbound.
Patients were randomized to tirzepatide or placebo for 52 weeks. At the end of the trial, tirzepatide was associated with significant improvements in several key measures:
The GLP-1/GIP receptor agonist also improved kidney function, with an estimated 2.9 mL/min/1.73 m2 increase in estimated glomerular filtration rate (eGFR) by the end of the study compared with placebo (P = .004). Patients also experienced a 25% reduction in the urine albumin-creatinine ratio at 24 weeks (P < .001), reflecting a decline in albuminuria and kidney stress, though this number dropped to a 15% reduction at 52 weeks (P = .051).
“Collectively, these observations suggest that novel treatments that reduce circulatory volume–pressure overload (or its determinants), improve kidney function, reduce inflammation and mitigate cardiac injury may improve clinical status in people with obesity-related HFpEF,” the research authors wrote.
Linking Mechanisms to Clinical Improvements
The reductions in blood volume, inflammation, and markers of cardiac and kidney injury were linked to better clinical outcomes for patients receiving tirzepatide. Improvements in volume overload correlated with enhanced scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ), which measures symptoms and quality of life. These patients also saw an average improvement of 18.3 meters in the 6-minute walk distance test, highlighting better exercise capacity after use of the GLP-1/GIP receptor agonist.
According to the researchers, these improvements in circulatory volume expansion may stem from tirzepatide’s ability to reduce adipocyte-released factors like leptin and aldosterone, which promote sodium retention and contribute to volume overload.
“Volume expansion in obesity-related HFpEF exacerbates elevation in cardiac filling pressures that develop due to impairments in left ventricular distensibility, and thus, reducing circulating volume may decrease cardiac filling pressures,” they said. “This finding could partly explain the direct correlation observed between reductions in BV [blood volume] and improvements in KCCQ-CSS score and exercise capacity.”
The trial also explored the relationship between inflammation and myocardial injury. Tirzepatide reduced levels of troponin T, a biomarker of cardiac injury, by 10.4% after 52 weeks (P = .003). The decline in troponin T was correlated with lower CRP levels, suggesting that the drug’s anti-inflammatory effects may contribute to reducing cardiac stress.
While tirzepatide’s effects on heart and kidney health are promising, longer-term studies are needed to confirm the durability of these benefits. Additionally, the study authors noted that more research is needed to understand how weight loss, a key effect of tirzepatide, contributes to the observed improvements in volume overload and inflammation.
References
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
ICYMI: Highlights From SPD 2024
December 30th 2024The Society for Pediatric Dermatology (SPD) Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating misinformation and improving care for children with dermatologic conditions.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
ICYMI: Highlights From SPD 2024
December 30th 2024The Society for Pediatric Dermatology (SPD) Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating misinformation and improving care for children with dermatologic conditions.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
2 Commerce Drive
Cranbury, NJ 08512